NCT04187430 (Clostri_Score) is a clinical trial of Retrospective in Clostridium Difficile Infection, sponsored by Emilio Bouza.

Who is sponsoring NCT04187430?

NCT04187430 is sponsored by Emilio Bouza.

What drugs are being tested in NCT04187430?

Interventions in NCT04187430: Retrospective, Prospective.

What condition does NCT04187430 study?

NCT04187430 studies Clostridium Difficile Infection.

Is NCT04187430 still recruiting?

NCT04187430 is currently status unknown. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT04187430: Clostri_Score

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies

Status unknown Last updated 29 July 2020

What this trial tests

trial testing Retrospective in Clostridium Difficile Infection in 513 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Emilio Bouza
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	513
Start date	1 December 2019
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Spain

Drugs / interventions tested

Retrospective
Prospective — full drug profile →

Conditions studied

Clostridium Difficile Infection — all drugs for Clostridium Difficile Infection →

Sponsor

Emilio Bouza

Who can join

18 and older, any sex, with Clostridium Difficile Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the present study is to derive a high-risk R-ICD prediction rule and a prospective implementation of this prediction rule.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Retrospective

Trials testing the same drug.

NCT06871618 — Retrospective Study of Surgical Induced Abortions Between 14 and 16 Weeks of Amenorrhea At Croix Rousse University Hospi · completed
NCT05569356 — Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE) · not yet recruiting

Other recruiting trials for Clostridium Difficile Infection

Currently open trials in the same condition.

NCT07221370 — Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients · Phase 2, PHASE3 · recruiting
NCT06703918 — Study on Clostridium Difficile Infection in Infants · recruiting
NCT04305769 — Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) · Phase 2 · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting
NCT03562741 — Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile · NA · recruiting

Other Emilio Bouza trials

Trials by the same sponsor.

NCT04196608 — In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and E · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04187430 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emilio Bouza
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing